Immunotherapy Agents in Pancreatic Cancer

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.

Margaret A. Tempero, MD, director, Pancreas Center, University of California, San Francisco, discusses the potential for immunotherapies in pancreatic cancer.

Clinical Pearls:

  • Developing immunotherapy agents in this space is a work in progress
  • Investigators at Johns Hopkins University School of Medicine have been looking at an autologous cell-based vaccine
  • Antigen-specific vaccines are also in development for pancreatic cancer
  • There is a need to “make room” for immunotherapies and determine their optimal use, especially with regard to immune checkpoint inhibitors, such as PD-1 and anti-CTLA-4